Last reviewed · How we verify
Non-insulin anti-diabetic treatment — Competitive Intelligence Brief
marketed
Diabetes
Small molecule
Live · refreshed every 30 min
Target snapshot
Non-insulin anti-diabetic treatment (Non-insulin anti-diabetic treatment) — Sanofi. Non-insulin anti-diabetic treatments work through various mechanisms to lower blood glucose by enhancing insulin secretion, improving insulin sensitivity, reducing hepatic glucose production, or slowing carbohydrate absorption.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Non-insulin anti-diabetic treatment TARGET | Non-insulin anti-diabetic treatment | Sanofi | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Non-insulin anti-diabetic treatment CI watch — RSS
- Non-insulin anti-diabetic treatment CI watch — Atom
- Non-insulin anti-diabetic treatment CI watch — JSON
- Non-insulin anti-diabetic treatment alone — RSS
Cite this brief
Drug Landscape (2026). Non-insulin anti-diabetic treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/non-insulin-anti-diabetic-treatment. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab